1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Autifony Therapeutics Ltd.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2011

Location

Hertfordshire UK

Primary Industry

Biotechnology

About

Based in Hertfordshire, UK, and founded in 2011 by CEO Charles H. Large, and CRO Charles H. Large, Autifony Therapeutics Ltd., a.k.a. Autifony Therapeutics is a clinical-stage biotechnology company that focuses on developing medicines to address rare genetic CNS disorders through its ion channel drug discovery platform. In March 2017, Autifony Therapeutics Ltd. raised GBP 1.3 million in funding from Innovate UK and the Dementia Discovery Fund. The company's primary product pipeline consists of clinical-stage, small-molecule modulators targeting the Kv3 family of potassium channels. These modulators are expected to demonstrate efficacy in treating Fragile X syndrome and rare myoclonic epilepsy syndromes. Additionally, Autifony has preclinical programs utilizing novel Kv3 modulators with potential applications in various CNS disorders, such as schizophrenia and hearing loss.
Current Investors
SV Health Investors, GlaxoSmithKline, Touchstone Innovations

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Specialty Pharmaceuticals
Website
www.autifony.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.